Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

Despite facing substantial headwinds, Pfizer's strategic pivot away from pandemic-related products is showing early signs of success. The company's second-quarter 2025 results revealed a 10% year-over ...

Two new real-world studies estimate the effectiveness of a single dose of a respiratory syncytial virus (RSV) vaccine against ...

This year’s Fierce Pharma Marketing Awards ceremony, which took place in Philadelphia on Wednesday night, saw several major ...

Match emojis with their word pairs in today’s puzzle challenge. Strengthen memory, sharpen focus, and test your visual recognition skills with this fun and engaging brain game.